Acquisition by Botwood Nicholas A.j. of 11765 shares of Syndax Pharmaceuticals at 8.995 subject to Rule 16b-3
| SNDX Stock | USD 12.57 2.19 21.10% |
Slightly above 55% of Syndax Pharmaceuticals' investors are presently thinking to get in. The analysis of overall sentiment of trading Syndax Pharmaceuticals stock suggests that some investors are interested at this time. Syndax Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Syndax Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Filed transaction by Syndax Pharmaceuticals Officer: Head Of R&d, Cmo. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at macroaxis.com
Syndax Pharmaceuticals Fundamental Analysis
We analyze Syndax Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Syndax Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Syndax Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Debt
Total Debt Comparative Analysis
Syndax Pharmaceuticals is currently under evaluation in total debt category among its peers. Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Syndax Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Syndax Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Syndax Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Syndax Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Syndax Pharmaceuticals Related Equities
| REPL | Replimune | 10.68 | ||||
| MRSN | Mersana Therapeutics | 2.62 | ||||
| MRUS | Merus BV | 2.09 | ||||
| KURA | Kura Oncology | 0.63 | ||||
| PTGX | Protagonist Therapeutics | 0.13 | ||||
| CTMX | CytomX Therapeutics | 0.84 |
Additional Tools for Syndax Stock Analysis
When running Syndax Pharmaceuticals' price analysis, check to measure Syndax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syndax Pharmaceuticals is operating at the current time. Most of Syndax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syndax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syndax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syndax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.